Frontline treatment of multiple myeloma

Rafael Fonseca

doi:10.1179/102453312X13336169156096

Frontline treatment of multiple myeloma

Rafael Fonseca

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The treatment of myeloma has been revolutionized by the availability of new drugs. Combination therapy followed by stem cell transplant holds the promise of ultimately curing a fraction of patients. Objective responses are the norm for induction therapy and up to 50% of patients achieve a complete remission. Ongoing clinical trials continue to address the role of long term maintenance therapy. Understanding the proper management of these agents is paramount to providing patients disease control and yet minimizing side effects from treatment.

Original language	English (US)
Pages (from-to)	S101-S104
Journal	Hematology
Volume	17
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1179/102453312X13336169156096
State	Published - Apr 2012

Keywords

Bortezomib
Induction
Lenalidomide
Myeloma
Transplant

ASJC Scopus subject areas

Hematology

Access to Document

10.1179/102453312X13336169156096

Cite this

@article{941d1a58cec34797b4e89ddd0d012d9d,

title = "Frontline treatment of multiple myeloma",

abstract = "The treatment of myeloma has been revolutionized by the availability of new drugs. Combination therapy followed by stem cell transplant holds the promise of ultimately curing a fraction of patients. Objective responses are the norm for induction therapy and up to 50% of patients achieve a complete remission. Ongoing clinical trials continue to address the role of long term maintenance therapy. Understanding the proper management of these agents is paramount to providing patients disease control and yet minimizing side effects from treatment.",

keywords = "Bortezomib, Induction, Lenalidomide, Myeloma, Transplant",

author = "Rafael Fonseca",

year = "2012",

month = apr,

doi = "10.1179/102453312X13336169156096",

language = "English (US)",

volume = "17",

pages = "S101--S104",

journal = "Hematology",

issn = "1024-5332",

publisher = "Taylor and Francis Ltd.",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Frontline treatment of multiple myeloma

AU - Fonseca, Rafael

PY - 2012/4

Y1 - 2012/4

N2 - The treatment of myeloma has been revolutionized by the availability of new drugs. Combination therapy followed by stem cell transplant holds the promise of ultimately curing a fraction of patients. Objective responses are the norm for induction therapy and up to 50% of patients achieve a complete remission. Ongoing clinical trials continue to address the role of long term maintenance therapy. Understanding the proper management of these agents is paramount to providing patients disease control and yet minimizing side effects from treatment.

AB - The treatment of myeloma has been revolutionized by the availability of new drugs. Combination therapy followed by stem cell transplant holds the promise of ultimately curing a fraction of patients. Objective responses are the norm for induction therapy and up to 50% of patients achieve a complete remission. Ongoing clinical trials continue to address the role of long term maintenance therapy. Understanding the proper management of these agents is paramount to providing patients disease control and yet minimizing side effects from treatment.

KW - Bortezomib

KW - Induction

KW - Lenalidomide

KW - Myeloma

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=84859780337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859780337&partnerID=8YFLogxK

U2 - 10.1179/102453312X13336169156096

DO - 10.1179/102453312X13336169156096

M3 - Article

C2 - 22507793

AN - SCOPUS:84859780337

SN - 1024-5332

VL - 17

SP - S101-S104

JO - Hematology

JF - Hematology

IS - SUPPL. 1

ER -

Frontline treatment of multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this